Pharmaceuticals Alcon grows faster again in the third quarter
The eye care group Alcon gained some momentum in the third quarter. Not least the newly launched products sold well. The annual targets have now been confirmed after two recent profit warnings.
11.11.2025, 22:55
SDA
From July to September, the US-Swiss group achieved sales of 2.59 billion US dollars. This corresponds to an increase of 6 percent, as reported on Tuesday after the close of the US stock exchange. In local currency, the increase amounted to 5 percent.
In the first half of the year, Alcon had only grown by 3 percent in local currencies. In the press release, the company emphasizes that demand has accelerated considerably, particularly in the "Equipment" segment. According to CEO David Endicott, the "Unity VCS", a surgical platform for eye operations, has gained in importance in all key markets.
However, the launch of the many new products is costly, as can be seen from the margin. The core margin as a measure of profitability fell to 20.2 percent from 20.6 percent. The bottom line is a core profit of 79 cents per share after 81 cents in the previous year.
This means that the company's turnover fell slightly short of analysts' expectations, while its margin and net profit were slightly higher.
After two recent profit warnings, the targets for 2025 have now been confirmed. Alcon expects sales of 10.3 to 10.4 billion dollars and a margin of 19.5 to 20.5 percent in the current year.
In comparison: in 2024, the company achieved sales of 9.8 billion and a margin of 20.6 percent.
